FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
59.037,17 -694,36 (-1,16%)
Aptose Biosciences Inc. (APTO)
| Chiusura precedente | 1,1600 |
| Aperto | 1,1600 |
| Denaro | 1,1900 x 100 |
| Lettera | 1,2600 x 100 |
| Min-Max giorno | 1,1600 - 1,2700 |
| Intervallo di 52 settimane | 0,3600 - 6,6000 |
| Volume | |
| Media Volume | 80.260 |
| Capitalizzazione | 19,562M |
| Beta (5 anni mensile) | 1,42 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -7,5800 |
| Prossima data utili | 06 mag 2024 - 10 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 12,00 |
GlobeNewswireAptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference
Company to Hold Clinical Update Webcast; Details ForthcomingSAN DIEGO and TORONTO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that two abstracts on tuspetinib, Aptose’s Phase 1/2 myeloid kinase inhibitor in development for acute myeloid leukemia (AML), have been accepted for post
- GlobeNewswire
Aptose to Present at the Cantor Global Healthcare Conference
SAN DIEGO and TORONTO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the Aptose management team will participate in the Cantor Global Healthcare Conference being held September 26-28, 2023, in New York City. Dr. William G. Rice, Chairman, President and CEO of Aptose, will part
- GlobeNewswire
Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical
— TUS/VEN doublet continues safe and effective in AML patients who failed prior venetoclax —SAN DIEGO and TORONTO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced closing of a $3 million investment in common shares of the Company (the “Shares”) as the first tranche of a private equity
